Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TX › Dallas › NPI 1265418669
Lab

Laboratory Corporation of America

Laboratory Corporation of America was paid $77.42M by Medicaid between Jan 2018 and Dec 2024, across 392 billing codes. Its largest line is 80050, General health panel — 7.5% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA
DALLAS, TX 75230
33aNPI1265418669assigned 12/16/2005
33bProvider typeClinical Medical Laboratory
28Total paid$77.42M
24GClaims9,486,407
24DCodes billed392
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#8 of 436
Median peer was paid$17K
This provider vs. median4,488×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018811,011$4.17M
2019756,695$3.96M
2020905,537$7.00M
20211,853,519$15.60M
20221,897,172$17.36M
20231,868,180$16.37M
2024incomplete1,394,293$12.97M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80050 General health panel 7.5% 268,217 255,169 $5.78M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.9% 207,949 194,893 $4.56M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.5% 203,002 190,334 $4.24M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 5.5% 79,365 63,614 $4.23M
80081 4.3% 69,931 65,889 $3.34M
80061 Lipid panel 4.2% 616,444 584,554 $3.27M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 4.1% 13,652 12,506 $3.14M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.8% 271,976 253,972 $2.96M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.5% 195,977 184,764 $2.67M
84443 Thyroid stimulating hormone (TSH) 2.8% 339,863 321,718 $2.14M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 2.7% 100,341 94,571 $2.12M
80053 Comprehensive metabolic panel 2.7% 561,291 520,963 $2.08M
380 more codes
83036 Hemoglobin; glycosylated (A1C) 2.4% 438,705 $1.87M
87086 Culture, bacterial; quantitative colony count, urine 2.3% 398,620 $1.77M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.3% 594,004 $1.77M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 2.0% 99,826 $1.58M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.7% 4,772 $1.31M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.6% 54,022 $1.20M
87150 1.6% 58,796 $1.20M
80074 1.2% 45,653 $944K
86803 1.1% 114,497 $878K
84439 <1% 186,296 $771K
87081 <1% 185,410 $745K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 19,273 $685K
87536 <1% 13,472 $538K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 32,893 $536K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 9,117 $528K
87186 <1% 118,493 $508K
87070 <1% 98,567 $501K
86235 <1% 11,317 $477K
87088 <1% 121,519 $473K
84702 <1% 54,525 $461K
82607 <1% 83,073 $460K
82728 <1% 76,218 $423K
84403 <1% 32,109 $419K
86480 <1% 13,758 $415K
86592 <1% 158,896 $406K
86696 <1% 24,112 $304K
87340 <1% 54,290 $297K
82670 <1% 19,841 $290K
84481 <1% 34,625 $275K
82746 <1% 50,292 $269K
82950 <1% 92,091 $257K
86376 <1% 26,816 $257K
87077 <1% 70,782 $249K
84153 <1% 38,052 $249K
83550 <1% 71,336 $246K
80055 <1% 6,714 $241K
83001 <1% 25,257 $240K
84402 <1% 16,846 $237K
85027 <1% 72,638 $231K
86850 <1% 40,870 $230K
86038 <1% 37,718 $225K
84146 <1% 22,583 $219K
84436 <1% 82,506 $216K
87522 Neg quan hep c or qual rna <1% 9,066 $208K
83540 <1% 87,368 $208K
86762 <1% 25,122 $204K
83525 <1% 34,926 $199K
83970 <1% 23,046 $199K
86003 <1% 4,632 $198K
87209 <1% 16,757 $197K
84144 <1% 17,251 $194K
86160 <1% 12,097 $189K
88141 <1% 13,579 $187K
86787 <1% 23,908 $183K
83002 <1% 19,156 $179K
83880 <1% 14,738 $172K
86780 <1% 22,821 $170K
86800 <1% 14,680 $165K
81001 <1% 120,553 $158K
82570 <1% 90,919 $154K
86147 <1% 4,444 $152K
80048 Basic metabolic panel (calcium, ionized) <1% 58,202 $150K
86695 <1% 18,676 $143K
84479 <1% 51,291 $142K
83020 <1% 20,897 $140K
84480 <1% 21,112 $139K
86665 <1% 6,601 $132K
82951 <1% 18,289 $132K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 6,806 $131K
86140 <1% 56,877 $131K
82043 <1% 67,243 $129K
86361 <1% 10,327 $114K
86677 <1% 8,984 $109K
80164 <1% 19,462 $108K
87427 <1% 14,376 $107K
87177 <1% 17,048 $106K
82784 <1% 12,679 $99K
83735 <1% 43,418 $99K
82105 <1% 12,959 $98K
86360 <1% 5,590 $98K
81329 <1% 2,903 $97K
81490 <1% 285 $96K
82627 <1% 7,545 $95K
87902 <1% 659 $91K
87045 <1% 14,546 $90K
86618 <1% 5,158 $89K
83021 <1% 7,214 $85K
87075 <1% 15,886 $85K
86706 <1% 15,206 $83K
86704 <1% 13,733 $82K
86431 <1% 25,448 $79K
86769 <1% 3,576 $78K
83655 <1% 12,224 $77K
86225 <1% 10,963 $76K
84450 <1% 42,971 $74K
82947 <1% 44,869 $74K
87046 <1% 14,551 $73K
82247 <1% 42,541 $72K
87625 <1% 3,314 $71K
85660 <1% 20,069 $71K
85652 <1% 56,454 $70K
82565 <1% 43,276 $69K
84550 <1% 44,579 $66K
81361 <1% 1,137 $66K
86901 <1% 27,257 $64K
83690 <1% 19,659 $63K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 2,239 $62K
82533 <1% 6,700 $59K
84460 <1% 34,503 $59K
82248 <1% 36,353 $58K
86200 <1% 8,374 $57K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 1,859 $57K
86870 <1% 4,042 $54K
80076 <1% 17,042 $53K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 497 $52K
88142 <1% 3,971 $51K
84156 <1% 39,983 $50K
84075 <1% 30,344 $50K
82040 <1% 32,290 $50K
85610 <1% 32,781 $49K
86900 <1% 27,349 $49K
87329 <1% 5,036 $49K
83013 <1% 1,371 $49K
86664 <1% 5,195 $49K
83516 <1% 4,957 $48K
82150 <1% 16,405 $46K
86334 <1% 5,917 $46K
85018 <1% 33,297 $46K
80069 <1% 25,353 $45K
82310 <1% 28,257 $45K
84520 <1% 33,203 $44K
82330 <1% 4,756 $42K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 834 $41K
84155 <1% 31,288 $40K
81243 <1% 2,834 $40K
82677 <1% 1,887 $39K
84295 <1% 23,322 $38K
84165 <1% 9,483 $38K
86708 <1% 7,172 $37K
87563 <1% 2,462 $37K
83615 <1% 17,845 $37K
82952 <1% 16,379 $37K
85060 <1% 2,795 $37K
82435 <1% 24,614 $37K
82977 <1% 18,052 $33K
82785 <1% 3,605 $33K
84100 <1% 27,679 $33K
85730 <1% 12,619 $32K
82550 <1% 15,532 $32K
82378 <1% 5,510 $32K
87101 <1% 7,411 $31K
81257 <1% 1,145 $31K
80178 <1% 9,232 $31K
85045 <1% 16,274 $31K
87210 <1% 8,334 $31K
82672 <1% 2,424 $30K
81003 <1% 32,482 $30K
84681 <1% 3,205 $30K
83520 <1% 2,945 $30K
84466 <1% 4,828 $30K
84703 <1% 6,593 $29K
36415 Collection of venous blood by venipuncture <1% 188,159 $28K
83521 <1% 2,844 $27K
86593 <1% 10,869 $27K
84432 <1% 2,144 $27K
80354 <1% 1,389 $27K
82024 <1% 1,731 $27K
80348 <1% 1,371 $27K
87324 <1% 4,220 $26K
86336 <1% 1,847 $25K
82140 <1% 5,242 $25K
82274 <1% 2,972 $24K
86778 <1% 2,832 $24K
84154 <1% 4,256 $23K
83498 <1% 1,447 $23K
86317 <1% 3,606 $23K
84132 <1% 15,078 $23K
82731 <1% 785 $21K
82103 <1% 2,510 $21K
86645 <1% 2,260 $21K
84270 <1% 1,679 $21K
85014 <1% 12,988 $19K
86644 <1% 2,353 $19K
80156 <1% 4,662 $18K
82390 <1% 3,083 $18K
86300 <1% 1,790 $18K
82374 <1% 10,128 $18K
80185 <1% 4,592 $18K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 154 $17K
80177 <1% 3,871 $17K
84134 <1% 3,178 $16K
87184 <1% 3,405 $15K
86757 <1% 597 $15K
82239 <1% 1,668 $15K
86141 <1% 2,578 $15K
86364 <1% 1,606 $14K
86705 <1% 2,615 $14K
82172 <1% 2,299 $14K
87650 <1% 1,044 $14K
86777 <1% 1,927 $14K
81330 <1% 1,120 $14K
81200 <1% 1,121 $13K
81255 <1% 1,121 $13K
83721 <1% 4,403 $13K
87338 <1% 1,671 $13K
86146 <1% 485 $13K
80051 <1% 6,553 $13K
81251 <1% 1,121 $12K
86702 <1% 1,659 $12K
80324 <1% 1,075 $12K
85379 <1% 2,266 $12K
80358 <1% 1,273 $12K
82465 <1% 5,898 $12K
86304 <1% 1,409 $12K
86709 <1% 2,228 $12K
86060 <1% 2,901 $12K
81290 <1% 1,120 $12K
81209 <1% 1,120 $11K
86008 <1% 217 $11K
86735 <1% 1,900 $11K
86765 <1% 1,979 $11K
81242 <1% 1,122 $11K
82652 <1% 1,518 $11K
80359 <1% 1,180 $11K
80197 <1% 5,703 $10K
81260 <1% 1,122 $10K
83883 <1% 2,940 $10K
87521 Neg quan hep c or qual rna <1% 303 $10K
86663 <1% 1,247 $10K
87660 <1% 697 $9K
89055 <1% 2,887 $9K
87205 <1% 4,362 $9K
86308 <1% 2,633 $9K
84482 <1% 860 $9K
87535 <1% 463 $9K
84478 <1% 3,908 $9K
87480 <1% 682 $8K
83090 <1% 1,341 $8K
87206 <1% 2,917 $8K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 2,430 $8K
86258 <1% 430 $8K
80349 <1% 719 $7K
86701 <1% 1,613 $7K
82668 <1% 1,090 $7K
81025 <1% 1,297 $6K
87328 <1% 566 $6K
84425 <1% 795 $6K
80347 <1% 584 $6K
87510 <1% 667 $6K
80361 <1% 728 $6K
87529 <1% 254 $6K
82104 <1% 559 $5K
85246 <1% 307 $5K
86301 <1% 647 $5K
86666 <1% 354 $5K
85041 <1% 2,602 $5K
80365 <1% 675 $5K
83010 <1% 969 $5K
86694 <1% 506 $5K
85048 <1% 3,199 $5K
83718 <1% 1,326 $4K
84484 <1% 747 $4K
82679 <1% 205 $4K
83921 <1% 517 $4K
85245 <1% 205 $4K
84410 <1% 103 $4K
80373 <1% 554 $4K
86256 <1% 281 $4K
86381 <1% 496 $4K
85240 <1% 272 $4K
84166 <1% 883 $4K
85384 <1% 622 $4K
87040 <1% 712 $4K
82575 <1% 828 $4K
88112 <1% 71 $4K
80175 <1% 915 $3K
82626 <1% 317 $3K
80372 <1% 485 $3K
80183 <1% 603 $3K
80353 <1% 522 $3K
87799 <1% 776 $3K
82157 <1% 161 $3K
84305 <1% 268 $3K
81401 <1% 35 $3K
87076 <1% 586 $3K
83527 <1% 404 $3K
80202 <1% 525 $2K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 785 $2K
80364 <1% 105 $2K
84445 <1% 107 $2K
85007 <1% 1,785 $2K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 317 $2K
86015 <1% 539 $2K
80334 <1% 105 $2K
80337 <1% 105 $2K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 154 $2K
81374 <1% 97 $2K
80370 <1% 105 $2K
85049 <1% 792 $2K
86359 <1% 238 $2K
87350 <1% 492 $2K
80326 <1% 105 $2K
80360 <1% 120 $2K
82553 <1% 365 $2K
80366 <1% 119 $2K
80338 <1% 105 $2K
80368 <1% 105 $2K
82610 <1% 276 $2K
80355 <1% 119 $2K
83992 <1% 105 $2K
88342 <1% 45 $2K
86335 <1% 152 $1K
80184 <1% 445 $1K
82985 <1% 299 $1K
80165 <1% 292 $1K
82787 <1% 227 $1K
82397 <1% 164 $1K
86747 <1% 70 $1K
84163 <1% 102 $1K
86037 <1% 154 $1K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 3,438 $1K
87493 <1% 52 $951.72
83993 <1% 70 $824.09
83695 <1% 101 $799.64
81015 <1% 328 $778.08
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 9,485 $769.87
86707 <1% 236 $750.63
82166 <1% 32 $705.34
88341 <1% 17 $688.08
85613 <1% 165 $653.17
82642 <1% 29 $629.84
86880 <1% 309 $583.38
86753 <1% 55 $581.28
80320 <1% 42 $437.94
87517 <1% 39 $427.05
81596 <1% 600 $411.29
85004 <1% 283 $400.72
87109 <1% 29 $387.92
80162 <1% 155 $358.29
87807 <1% 35 $350.86
83014 <1% 88 $333.42
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 1,994 $332.16
87116 <1% 93 $326.84
87538 <1% 13 $318.73
86255 <1% 56 $291.51
83605 <1% 39 $269.76
80201 <1% 106 $241.38
85385 <1% 37 $238.71
84080 <1% 26 $228.09
87425 <1% 25 $221.60
84630 <1% 39 $218.98
G0475 Hiv antigen/antibody, combination assay, screening <1% 1,426 $212.36
87015 <1% 86 $202.25
84140 <1% 12 $197.49
82232 <1% 38 $181.37
80371 <1% 25 $170.29
80357 <1% 25 $169.03
80367 <1% 25 $163.62
80341 <1% 39 $154.18
87106 <1% 47 $140.70
82085 <1% 38 $130.81
80377 <1% 25 $126.60
80344 <1% 25 $125.99
87420 <1% 20 $121.95
80331 <1% 25 $111.57
82525 <1% 26 $107.85
82705 <1% 29 $77.66
80195 <1% 13 $64.66
85670 <1% 31 $60.41
80235 <1% 13 $55.51
85732 <1% 14 $37.74
83935 <1% 12 $33.91
83930 <1% 12 $33.44
84300 <1% 12 $14.67
86682 0% 39 $0.00
87497 0% 14 $0.00
99199 Unlisted special service, procedure or report 0% 36 $0.00
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous 0% 96 $0.00
36416 0% 338 $0.00
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision 0% 51 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.